AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

RYAAY flew 17.5 million passengers in April 2025, up 8% year over year, though its load factor dipped to 92%.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

We initiate coverage on fuboTV with a Strong Buy, believing the market underestimates the scale and timing of the Disney + Hulu integration catalyst into FY26. Our implied valuation is supported by a 2.8x target Price/Sales multiple on our FY26E US$2.335bn revenue forecast for FUBO, representing a warranted premium to both historical and peer averages. We estimate US$1.46bn in FY25E revenue generation and accelerate to US$2.35bn in FY26E, materially ahead of consensus.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=151461&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.

SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, an unprecedented 33% (32 of 97) of patients remained progression-free for five years or more.

ROCHESTER, N.Y. , June 3, 2025 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of AI-powered smart glasses, waveguides and Augmented Reality (AR) technologies, today announced that the Company and Wyr.ai Private Limited ("Wyr.ai"), a trailblazing XR and AI product company that revolutionizes industries through cutting-edge technology, have partnered to launch a new AI-driven quality assurance inspection platform that uses Vuzix M400™ smart glasses.

Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These …

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent.

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO ® in transplant-ineligible newly diagnosed patients CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly …

SAIC stock declines 13% after Q1 earnings miss, flat profits and margin pressure weigh despite modest revenue growth.

HLT hits 1,000 luxury hotels, adds new brands and global partnerships, with 500 more in its upscale pipeline.

SHANGHAI, and NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- TH International Limited (“Tims China” (Nasdaq: THCH)), the exclusive operator of Tim Hortons coffee shops in China, plans to release its first quarter results before market opening on Tuesday June 24, 2025, with a conference call to follow at 8:00 AM EST or 8:00 PM China Standard Time. The conference call will be webcast, and can be accessed on the company website at https://ir.timschina.com/events-presentations/presentations-webcasts.

Issues Letter to TURN Shareholders Detailing Continued Governance Failures and Mismanagement by 180 Board and Management Team CHICAGO , June 3, 2025 /PRNewswire/ -- Marlton Partners L.P. (together with its affiliates and group members, "Marlton" or "we"), beneficial owners of approximately 5.2% of the outstanding stock of 180 Degree Capital Corp. (NASDAQ: TURN) (the "Company"), today issued an open letter calling on the TURN Board of Directors to immediately set a record date and allow shareholders to vote on the Company's proposed sale to Mount Logan Capital Inc. (Cboe Canada: MLC) ("Mount Logan"): Dear Fellow Shareholders of 180 Degree Capital …